REM Sleep Behavior Disorder Market Set to Grow Significantly by 2034 Across the 7MM | DelveInsight

DelveInsight's "REM Sleep Behavior Disorder Market Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of REM Sleep Behavior Disorder epidemiology, market, and clinical development in RBD, along with historical and forecasted epidemiology and market data and a detailed analysis of the REM Sleep Behavior Disorder market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.

Explore the intricate details of the REM Sleep Behavior Disorder Market Report @ https://www.delveinsight.com/report-store/rem-sleep-behavior-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from REM Sleep Behavior Disorder Market Report
• The REM Sleep Behavior Disorder market is expected to grow at a significant CAGR by 2034 in leading countries like the US, EU4, UK, and Japan.
• RBD is a rare disorder, with a prevalence of about 0.5% to 1.5% overall; in adults aged 60 to 99, prevalence rises significantly, affecting approximately 5% to 13%.
• RBD can be classified into an idiopathic form (iRBD) and a secondary form, which occurs in patients already diagnosed with PD (25-58% of cases), DLB (70-80%), MSA (90-100%), autoimmune disease, and focal brainstem lesions.
• RBD has a strong male predominance in published series, as high as a 9:1 male-to-female ratio.
• No therapies are currently approved for RBD, mainly due to challenges like patient variability, lack of biomarkers, overlap with neurodegenerative diseases, limited translational models, and complexities in trial design.
• Currently, clonazepam and melatonin are used off-label as the standard-of-care, while pipeline therapies are in very early stages of development, focusing on modulating GABA, serotonin, and synuclein aggregation, and improving sleep architecture.
• The pipeline for treating RBD includes emerging therapies such as CST-103/CST-107 (CuraSen Therapeutics) and Tasimelteon (Vanda Pharmaceuticals), among others currently in development.
• In March 2024, CuraSen Therapeutics presented positive Phase IIa data on CST-107 targeting non-motor symptoms, including RBD, in patients with Alzheimer's or Parkinson's disease at the AD/PD 2024 International Conference.

Get a Free sample for the REM Sleep Behavior Disorder Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/rem-sleep-behavior-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What is REM Sleep Behavior Disorder?
RBD is a type of parasomnia marked by physically acting out dreams due to the absence of normal muscle paralysis (atonia) during REM sleep. These actions can pose significant risks of injury to both the affected individuals and their bed partners. RBD is commonly linked to antidepressant usage and conditions like narcolepsy, but the strongest connection is with neurodegenerative alpha-synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Notably, RBD symptoms can appear many years before the onset of these neurological conditions, making a detailed patient history crucial for early recognition.
A definitive diagnosis of RBD requires an overnight sleep study (polysomnography) with video monitoring to document abnormal REM sleep behaviors and rule out other sleep disorders. Management involves ensuring safety to prevent injury, addressing underlying causes, and, in severe cases, using medications such as melatonin or clonazepam.

REM Sleep Behavior Disorder Epidemiology Segmentation in the 7MM
• Total Diagnosed Prevalent Cases of REM Sleep Behavior Disorder
• Type-specific Diagnosed Prevalent Cases of REM Sleep Behavior Disorder
• Age-specific Diagnosed Prevalent Cases of REM Sleep Behavior Disorder
• Total Treatable Cases of REM Sleep Behavior Disorder
RBD occurs in the absence of an underlying neurological disorder and has a prevalence of 0.38% to 1.15% in the general population aged over 60 years. RBD is seen in about 30% of young people with narcolepsy type I. REM sleep without atonia (RSWA) affects around 2% of the general population, but it is more common in people on antidepressants (12%) and older men (25%). Among Japanese elderly people, the prevalence of iRBD was 1.23%, which fell in the range of prevalence reported from other countries. The estimated prevalence of iRBD in Spanish individuals aged 60 or older attending primary care centers is 0.74%.

Download the report to understand which factors are driving REM Sleep Behavior Disorder epidemiology trends @ https://www.delveinsight.com/report-store/rem-sleep-behavior-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

REM Sleep Behavior Disorder Approved Therapies
No therapies are currently approved for RBD, mainly due to challenges like patient variability, lack of biomarkers, overlap with neurodegenerative diseases, limited translational models, and complexities in trial design. Clonazepam and melatonin are currently used off-label as the standard-of-care, with melatonin (typically 3 to 12 mg at bedtime) preferred as first-line therapy for its effectiveness and favorable safety profile, particularly in older adults. Clonazepam is also effective but may lead to sedation, imbalance, or cognitive issues, especially in the elderly. Pramipexole is occasionally considered, though evidence for its benefit in RBD is limited. Ramelteon has shown subjective improvement in open-label studies of idiopathic RBD but did not significantly reduce dream enactment or abnormal REM activity.

REM Sleep Behavior Disorder Pipeline Analysis
• CST-103/CST-107 (NCT04739423): CuraSen Therapeutics
CuraSen Therapeutics is developing a novel combination therapy, CST-103 and CST-107, for patients with Parkinson's disease who also suffer from non-motor symptoms such as RBD and cognitive decline. CST-103 is a brain-penetrant β2-adrenergic receptor agonist aimed at restoring adrenergic signaling in the brain, paired with CST-107, a peripheral β-adrenergic receptor blocker that does not enter the brain to reduce potential side effects like elevated heart rate and blood sugar. This targeted approach allows CST-103 to act centrally while minimizing unwanted peripheral effects, offering a promising strategy to treat early non-motor symptoms of PD, particularly in patients with RBD. The therapy is currently in Phase IIa.

• Tasimelteon (NCT05922995): Vanda Pharmaceuticals
Tasimelteon, a melatonin receptor agonist, is currently being investigated in an early Phase I clinical trial for its potential role in managing RBD. The study is sponsored by Brigham and Women's Hospital, with support and collaboration from Vanda Pharmaceuticals, the developer of tasimelteon. This drug is already approved for certain circadian rhythm disorders, and its ability to regulate the sleep-wake cycle makes it a promising candidate for RBD. The ongoing trial aims to evaluate its safety, tolerability, and initial pharmacological effects in individuals with RBD.

REM Sleep Behavior Disorder Companies
CuraSen Therapeutics, Vanda Pharmaceuticals, and others

Discover more about therapies set to grab major REM Sleep Behavior Disorder market share @ https://www.delveinsight.com/sample-request/rem-sleep-behavior-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

REM Sleep Behavior Disorder Market Outlook
Rapid Eye Movement Sleep Behavior Disorder (RBD) is a chronic parasomnia in which the normal muscle paralysis during REM sleep is lost, causing dream-enactment behaviors that may result in injury. RBD is widely recognized as an early indicator of neurodegenerative disorders, including Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies. Currently, no FDA-approved therapies specifically target RBD, with treatment relying on off-label use of clonazepam and melatonin for symptom control. Emerging therapies, such as CuraSen's CST-103/107 and Vanda Pharmaceuticals' tasimelteon, are being investigated to target underlying neural dysfunction. Advancements in biomarkers and early diagnosis are expected to support disease-modifying strategies and expand the RBD treatment landscape.

Scope of the REM Sleep Behavior Disorder Market Report
• Study Period: 2020-2034
• Forecast Period: 2025-2034
• Coverage: 7MM (US, EU4 [Germany, France, Italy, and Spain], UK, and Japan)
• REM Sleep Behavior Disorder Companies: CuraSen Therapeutics, Vanda Pharmaceuticals, and others
• REM Sleep Behavior Disorder Therapies: CST-103/CST-107, Tasimelteon, and others
• REM Sleep Behavior Disorder Market: Segmented by region and therapies
• REM Sleep Behavior Disorder Market Analysis: KOL Views, SWOT Analysis, Reimbursement, Conjoint Analysis, Analyst Views, Unmet Needs

To know more about REM Sleep Behavior Disorder companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/rem-sleep-behavior-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Key Insights
2. Executive Summary of REM Sleep Behavior Disorder
3. Competitive Intelligence Analysis for REM Sleep Behavior Disorder
4. REM Sleep Behavior Disorder: Market Overview at a Glance
5. REM Sleep Behavior Disorder: Disease Background and Overview
6. Patient Journey
7. REM Sleep Behavior Disorder Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. REM Sleep Behavior Disorder Unmet Needs
10. Key Endpoints of REM Sleep Behavior Disorder Treatment
11. REM Sleep Behavior Disorder Marketed Products
12. REM Sleep Behavior Disorder Emerging Therapies
13. REM Sleep Behavior Disorder: Seven Major Market Analysis
14. Attribute Analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of REM Sleep Behavior Disorder
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.